TGF-ß2 silencing to target biliary-derived liver diseases.

Dropmann A., Dooley S., Dewidar B., Dediulia T., Werle J., Hartwig V., Hammad S., Ghafoory S., Wolfl S., Korhonen H., Janico M., Wosikowski K., Itzel T., Teufel A., Schuppan D., Stojanovic A., Cerwenka A., Nittka S., Piiper A., Gaiser T., Beraza N., Milkiewicz M., Mikliewicz P., Brain J. G., Jones D. E. J., Weiss T. S., Zanger U. M., Ebert M. P., Meindl-Beinker N. M.. (2020)

Gut

TGF-ß2 (TGF-ßtransforming growth factor beta), the less-investigated sibling of TGF-ß1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-ß2 in biliary-derived liver diseases.

Gut

View Publication